Inhibition of potassium-evoked release of cholecystokinin from rat caudate-putamen, cerebral cortex and hippocampus incubated in vitro by phencyclidine and related compounds
| Autor: | Margery C. Beinfeld, Lloyd R. Allard, J.S. Brog, Kenner C Rice, Jason C. Viereck, and Arthur E. Jacobson, Patricia C. Contreras |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Male
Telencephalon Dexoxadrol Sigma receptor Phencyclidine Hippocampus In Vitro Techniques Pharmacology medicine Animals Receptors sigma Molecular Biology Cholecystokinin Cerebral Cortex Chemistry General Neuroscience Putamen Rats Inbred Strains In vitro Rats medicine.anatomical_structure Pentazocine Cerebral cortex Receptors Opioid Potassium Neurology (clinical) Caudate Nucleus Neuroscience hormones hormone substitutes and hormone antagonists Developmental Biology medicine.drug |
| Zdroj: | Brain Research. 522:224-226 |
| ISSN: | 0006-8993 |
| DOI: | 10.1016/0006-8993(90)91464-r |
| Popis: | Potassium-evoked release of cholecystokinin (CCK) from slices of caudate-putamen, hippocampus, and cerebral cortex was inhibited in a dose-related fashion by phencyclidine (PCP). In order to further examine this effect, PCP-like ligands (dexoxadrol, levoxadrol, PCMP and MK-801) as well as compounds known to interact with the sigma receptor ((+)-SKF, DTG, (+)-3-PPP, and pentazocine) were tested. While some of these compounds inhibited CCK release, their rank order potency (Dex = Lev greater than PCP = PCMP greater than DTG = MK-801 = (+)-3-PPP) differs from that of known PCP-N-methyl-D-aspartate linked effects or sigma interactions. These results suggest that the mechanism by which PCP acts to inhibit CCK release may involve a novel type of PCP interaction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|